Acceder

Farmas USA

136K respuestas
Farmas USA
85 suscriptores
Farmas USA
Página
13.134 / 17.026
#105067

Re: Farmas USA

CELG

Investigational Data Presented at ASCO GI Evaluate ABRAXANE(R) Regimen for Patients with Locally Advanced Pancreatic Cancer

Phase II LAPACT trial results reported on the safety and efficacy of ABRAXANE + gemcitabine induction therapy on tumor burden, disease control, and symptoms

http://www.businesswire.com/news/home/20180119005472/en/

#105068

Re: Farmas USA

ACAD

Sí. Pero el primero es mucho menos significativo. Copio mensaje de IV que viene de este hilo:

https://www.investorvillage.com/smbd.asp?mb=523&mn=11411&pt=msg&mid=17848754

The MDD PhII reads out Sep; but given how good the SAGE 217 results were for MDD, ACAD may lose out on this indication. So not sure how pronounced the pps move might be.

The Schizo PhIII read out Dec. I plan to have a full position in place by end of Q3 at the latest, as I expect good results and a large pps effect given the market size.

#105070

Re: Farmas USA

Jeje si es que para 2 valores en los que entro CELG 325/104,90$ y ACAD 500/28,35$ me toca hold quiza mas largo que con otros...q importante la paciencia!

#105071

Re: Farmas USA

 

-----------------

Endpoints' John Carroll reports that FDA Commissioner Scott Gottlieb, M.D. has apparently backtracked on a confirmation hearing pledge to publish (redacted) Complete Response Letters (CRLs) as part of an overall push for greater agency transparency.

Hasta ahora en el mandato de Gottlieb, la FDA no ha publicado tres CRL.

 

https://seekingalpha.com/news/3322982-fda-commish-pivots-pledge-publish-crls?app=1&uprof=37#email_link

-

FDA 

No pasa nada hombre ya sabemos como cooperais con las mafias de dentro de las farma,

por suerte y para eso tenemos el AT,

....bueno lo suyo es  que fueses transparentes. ,,,,,